Zenotech Laboratories (BOM:532039) ROCE %: -6.40% (As of Mar. 2026)


BOM:532039 Zenotech Laboratories Ltd BOM:532039
73 GF Score
Price ₹45.91
GF Value ₹65.19
Valuation Significantly Undervalued
! 1 Warning Sign
View Full Analysis

What is Zenotech Laboratories ROCE %?

Zenotech Laboratories BOM:532039 +3.42% 73 ROCE % is -6.40% as of Mar. 2026. GuruFocus rates BOM:532039 with a GF Score™ of 73/100 and a GF Value™ of ₹65.19 (Significantly Undervalued). The stock has 1 warning sign investors should review.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Zenotech Laboratories's annualized ROCE % for the quarter that ended in Mar. 2026 was -6.40%.

Zenotech Laboratories  (BOM:532039) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Zenotech Laboratories ROCE % Related Terms

Zenotech Laboratories ROCE % Historical Data

* Premium members only.

The historical data trend for Zenotech Laboratories's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Zenotech Laboratories ROCE % Chart

Zenotech Laboratories Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
ROCE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 14.88 17.96 12.59 7.56 2.10

Zenotech Laboratories Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
ROCE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 11.14 5.19 5.09 10.47 -6.40
BOM:532039
73GF Score
Zenotech Laboratories Ltd BOM:532039
ROCE % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Zenotech Laboratories ROCE % Calculation

Zenotech Laboratories's annualized ROCE % for the fiscal year that ended in Mar. 2026 is calculated as:

ROCE %=EBIT/( (Capital Employed+Capital Employed)/ count )
(A: Mar. 2026 )  (A: Mar. 2025 )(A: Mar. 2026 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(A: Mar. 2026 )  (A: Mar. 2025 )(A: Mar. 2026 )
=20.751/( ( (1110.305 - 125.87) + (1111.535 - 120.564) )/ 2 )
=20.751/( (984.435+990.971)/ 2 )
=20.751/987.703
=2.10 %

Zenotech Laboratories's ROCE % of for the quarter that ended in Mar. 2026 is calculated as:

ROCE %=EBIT (1)/( (Capital Employed+Capital Employed)/ count )
(Q: Mar. 2026 )  (Q: Dec. 2025 )(Q: Mar. 2026 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(Q: Mar. 2026 )  (Q: Dec. 2025 )(Q: Mar. 2026 )
=-63.444/( ( (0 - 0) + (1111.535 - 120.564) )/ 1 )
=-63.444/( ( 0 + 990.971 )/ 1 )
=-63.444/990.971
=-6.40 %

(1) Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about ROCE % →
What does a ROCE % of -6.40% mean?
Zenotech Laboratories (BOM:532039) has a ROCE % of -6.40% as of Mar. 2026.
Is Zenotech Laboratories' ROCE % too high?
Zenotech Laboratories' current ROCE % is -6.40%. Overall, Zenotech Laboratories has a GF Score™ of 73/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Zenotech Laboratories' ROCE % compare to ZTS and UTHR?
Zenotech Laboratories' ROCE % of -6.40% can be compared against companies in the Drug Manufacturers industry. The industry median ROCE % is 7.02. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROCE % for a Drug Manufacturers company?
The median ROCE % among Drug Manufacturers companies is 7.02, based on 956 companies in the industry. Companies in the top quartile (top 25%) have a ROCE % significantly above this median, while those in the bottom quartile fall well below. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROCE % mean?
A high ROCE % can signal that a stock is expensive relative to its fundamentals. For the Drug Manufacturers industry, the median ROCE % is 7.02 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Zenotech Laboratories's current ROCE % is -6.40%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Zenotech Laboratories stock overvalued right now?
Based on GuruFocus' analysis, Zenotech Laboratories (BOM:532039) is currently considered Significantly Undervalued. The stock's GF Value™ is ₹65.19, compared to a current price of ₹45.91 — trading 29.6% below its estimated fair value. The current ROCE % is -6.40%. Zenotech Laboratories' overall GF Score™ is 73/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROCE % calculated?
ROCE % is calculated from a company's financial statements. For Zenotech Laboratories (BOM:532039), the current ROCE % is -6.40% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Zenotech Laboratories (BOM:532039) Overvalued in 2026?

Based on GuruFocus' analysis, Zenotech Laboratories stock appears to be undervalued. The current stock price of ₹45.91 is trading 29.6% below its estimated GF Value™ of ₹65.19. GuruFocus considers Zenotech Laboratories to be Significantly Undervalued.

Key valuation signals for BOM:532039:

  • ROCE %: -6.40%
  • GF Value™: ₹65.19 vs. price of ₹45.91 (29.6% below fair value)
  • GF Score™: 73/100 with 1 warning sign

No single metric tells the full story. See the BOM:532039 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Zenotech Laboratories Business Description

Address Survey No. 250-252, Turkapally Village, Shamirpet Mandal, RR District, Hyderabad, TG, IND, 500 078
Zenotech Laboratories Ltd is an India-based pharmaceutical company. It is a pharmaceutical specialty generic injectables company engaged in the area of manufacturing biotechnology products. The Company's injectables product portfolio serves niche therapy areas like oncology and anesthesiology. It also manufactures products such as granulocyte-colony stimulating factor (GCSF) and Granulocyte-macrophage colony-stimulating factor (GMCSF). The company earns a vast majority of the revenue from the sale of its contract research and manufacturing services.
73GF Score

Get the complete analysis for BOM:532039

ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹45.91
Price
₹65.19
GF Value